Leerink Partners Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)

January 8, 2026 3:59 AM EST Send to a Friend
Leerink Partners analyst Mani Foroohar reiterated a Market Perform rating and $15.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login